Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Por Damon Bass, Regina Kurrasch, Yin Su, Jie Zheng, Yang Li, Guochun Wang, Fengchun Zhang, David A Roth, Jieruo Gu, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik, Mingjun Wang, Xingfu Li
Publicado em 2022-04-01